Cytovation ASA bags additional US$6m to drive Phase II study
Cytovation ASA has baged US$6m to advance Phase II development of its bi-specific pore-forming peptide candidate CY-101 in patients with adrenocortical carcinoma.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1481 entries already.
Entries by Thomas Gabrielczyk
KKR makes US$1.22bn tender for Swedish Biotage AB
/in News/by Thomas GabrielczykRWK Bidco AB, newly founded by the private equity firm KKR (Kohlberg Kravis Roberts & Co.), has identified Swedish separation specialist Biotage AB as a takeover target and submitted an official takeover offer.
Boehringer Ingelheim inks deal with Tessallate Bio
/in News/by Thomas GabrielczykBoehringer Ingelheim and synthetic lethality specialist Tessellate Bio have entered into an €500m biobucks global license agreement on oral first-in-class cancer treatments.
Roche and Novartis react to US tariffs
/in News/by Thomas GabrielczykDespite the World Trade Organisation’s (WTO) ban of tariffs on pharmaceuticals, US President Donald Trump has announced he would consider imposing tariffs on pharmaceutical products. In a fast reaction, Swiss pharmaceutical giants Roche and Novartis, which are heavily dependent on the US market, have announced upcoming investments in the US as a production location by 2030.
Whey Waste Finds New Life as Protein
/in News/by Thomas GabrielczykFrench dairy heavyweight Bel Group has teamed up with Standing Ovation in a bid to transform surplus whey from cheese production into high-value casein proteins using precision fermentation. The collaboration is set to address the longstanding issue of under-utilised acid whey, a by-product that often goes to waste in the dairy sector.
AMT-130 gets FDA breakthrough therapy designation
/in News/by Thomas GabrielczykAmsterdam-based uniQure NV’s gene therapy candidate AMT-130 has been granted FDA Breakthrough Therapy Designation for the treatment of the neurodegenerative Huntington’s disease.
Netherlands Sets Sights on Global Biotech Leadership
/in News/by Thomas GabrielczykThe Netherlands has set itself an ambitious goal: to be among the global leaders in biotechnology by 2040. This vision is backed by an initial commitment of €1.3 billion in funding.
NLS and Kadimastem: Swiss-israeli merger in ALS
/in News/by Thomas GabrielczykNLS Pharmaceutics secures US$2m equity funding and signs US$25m equity facility to support merger with Kadimastem (Israel) to combine expertise in aiming to become a leader in regenerative medicine in neurodegenerative disorders.
Zürich, 31 March 2025 –
UK Government invests millions into new health data service
/in News/by Thomas GabrielczykUK focuses on digital health research: 600 british pounds (US$764m) for new data platform according to the five recommendations of the Sudlow report.
Swedish TIRmed Pharma raises 4,3m€ against atopic dermatitis
/in News/by Thomas GabrielczykTIRmed Pharma secures 4,3m€ to advance immunomodulatory treatment options for atopic dermatitis into clinical development. Stockholm-based TIRmed Pharma has closed this funding round, led by Sciety and its investment network, Sciety Venture Partners. The capital shall support the company’s progress toward clinical development of its novel treatment for atopic dermatitis.